Amgen Gets Romo FOMO

Amgen Gets Romo FOMO


A complete response letter for Amgen 's osteoporosis candidate romosozumab is hardly a surprise. More puzzling is the fact the company is seemingly pushing ahead with the project in spite of worries over serious cardiovascular events.



from Biotech News